术后监测乳腺MRI背景实质强化与未来第二乳腺癌风险相关
该回顾性研究纳入2668例有原发性乳腺癌手术史的女性,评估监测乳腺MRI的背景实质强化(BPE)与未来第二乳腺癌风险的关系。中位随访5.8年,109例发生第二乳腺癌;轻度及以上BPE、初诊年龄<45岁、BRCA1/2阳性及初诊激素受体阴性均与第二乳腺癌风险独立相关。
要点
- 监测乳腺MRI轻度及以上BPE与未来第二乳腺癌风险独立相关(HR 2.1)。
- BRCA1/2阳性者第二乳腺癌风险最高(HR 6.5),初诊年龄<45岁次之(HR 3.4)。
- 报告BPE时应按四分类(minimal/mild/moderate/marked)描述,有助于风险分层。
核心结论
- 监测乳腺MRI的BPE与有乳腺癌个人史女性的未来第二乳腺癌风险相关。
研究设计与样本
- 单中心回顾性研究,纳入2008年1月至2017年12月间连续监测乳腺MRI的2668例原发性乳腺癌术后女性(基线平均年龄49岁±8)。
- BPE采用四分类定性评估:minimal、mild、moderate、marked。
- 第二乳腺癌定义为每次监测MRI后至少1年诊断的同侧复发或对侧新发癌;采用多变量Fine-Gray竞争风险模型分析。
关键影像表现/征象
- BPE为影像征象,原文按minimal、mild、moderate、marked四类定性评估,未描述其他影像特征。
诊断标准与关键数值
- 轻度及以上BPE(mild/moderate/marked)与第二乳腺癌风险升高独立相关:HR 2.1(95%CI: 1.4, 3.1),P < .001。
- 初诊年龄<45岁:HR 3.4(95%CI: 1.7, 6.4),P < .001。
- BRCA1/2基因检测阳性:HR 6.5(95%CI: 3.5, 12.0),P < .001。
- 初诊乳腺癌激素受体阴性:HR 1.6(95%CI: 1.1, 2.6),P = .02。
临床应用与阅片要点
- 阅片时对监测乳腺MRI的BPE按四分类记录,轻度及以上者应提示临床关注第二乳腺癌风险。
- 结合初诊年龄、BRCA1/2状态和激素受体状态综合评估风险,辅助制定个体化监测方案。
局限性
- 单中心回顾性设计,BPE为定性评估,可能存在选择偏倚和评估者间差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Background Background parenchymal enhancement (BPE) is a known risk factor for breast cancer. However, studies on the association between BPE and second breast cancer risk are still lacking. Purpose To investigate whether BPE at surveillance breast MRI is associated with subsequent second breast cancer risk in women with a personal history of breast cancer. Materials and Methods A retrospective search of the imaging database of an academic medical center identified consecutive surveillance breast MRI examinations performed between January 2008 and December 2017 in women who underwent surgery for primary breast cancer and had no prior diagnosis of second breast cancer. BPE at surveillance breast MRI was qualitatively assessed using a four-category classification of minimal, mild, moderate, or marked. Future second breast cancer was defined as ipsilateral breast tumor recurrence or contralateral breast cancer diagnosed at least 1 year after each surveillance breast MRI examination. Factors associated with future second breast cancer risk were evaluated using the multivariable Fine-Gray subdistribution hazard model. Results Among the 2668 women (mean age at baseline surveillance breast MRI, 49 years ± 8 [SD]), 109 developed a second breast cancer (49 ipsilateral, 58 contralateral, and two ipsilateral and contralateral) at a median follow-up of 5.8 years. Mild, moderate, or marked BPE at surveillance breast MRI (hazard ratio [HR], 2.1 [95% CI: 1.4, 3.1]; P < .001), young age (<45 years) at initial breast cancer diagnosis (HR, 3.4 [95% CI: 1.7, 6.4]; P < .001), positive results from a BRCA1/2 genetic test (HR, 6.5 [95% CI: 3.5, 12.0]; P < .001), and negative hormone receptor expression in the initial breast cancer (HR, 1.6 [95% CI: 1.1, 2.6]; P = .02) were independently associated with an increased risk of future second breast cancer. Conclusion Background parenchymal enhancement at surveillance breast MRI was associated with future second breast cancer risk in women with a personal history of breast cancer. © RSNA, 2022 Online supplemental material is available for this article. See also the editorial by Niell in this issue.
引用
- Lee, Jang, Yoen, et al. Background Parenchymal Enhancement at Postoperative Surveillance Breast MRI: Association with Future Second Breast Cancer Risk. Radiology. 2022. PMID: 36040335. doi:10.1148/radiol.220440
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。